Richard D. Carvajal, MD

Tse AN, Carvajal R, Shah M, Dials H, Fogel M, O’Reilly E, Chung K, Maki R, Wu N, Egorin M, Schwartz GK. Phase 1 dose-escalation study of 17-allylamino-17-demethoxygeldanamycin (17AAG) in combination with irinotecan in patients with solid tumors. Proc Amer Soc Clin Oncol 2007. Vol 25, No 18A (June 20 Supp): Abs 3533.

Carvajal RD, Tse A, Wu N, Gonen M, Lefkowitz R, Dials H, Barbi A, Mui J, Schwartz GK, Shah M. Pharmacokinetics (PK) of split-dose flavopiridol (F) administered with CPT-11 (CPT) and cisplatin (Cis). Proc Amer Soc Clin Oncol 2007. Vol 25, No 18A (June 20 Supp): Abs 2578.

Meng RD, Carvajal R, Tse AN, Shah MA, Dials H, Brukner D, O'Reilly EM, Kelsen DP, Schwartz GK. A phase I clinical and pharmacokinetic study of flavopiridol administered concurrently with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) for advanced solid tumors. Proc Amer Soc Clin Oncol 2006. Vol 24, No 18S (June 20 Supp): Abs 13515.

Abou-Alfa GK, Carvajal RD, Chung KY, Ghossein RA, Capanu M, Gonen M, Jacobs G, Kelsen DP, Schwartz GK. A non-randomized phase II study of sequential irinotecan (CPT) and flavopiridol (F) in patients (pts) with advanced hepatocellular carcinoma (HCC). Proc Amer Soc Clin Oncol 2006. Vol 24, No 18S (June 20 Supp): Abs 4148.

Carvajal RD, Merrill AH, Dials H, Barbi A, Schwartz GK. A phase I clinical study of safingol followed by cisplatin: promising activity in refractory adrenocortical cancer with novel pharmacology. Proc Amer Soc Clin Oncol 2006. Vol 24, No 18S (June 20 Supp): Abs 13044.